MicroRNA Mediated Chemokine Responses in Human Airway Smooth Muscle Cells

Mythili Dileepan1, Anne E. Sarver2, Savita P. Rao1, Reynold A. Panettieri, Jr3, Subbaya Subramanian2, Mathur S. Kannan1*

1 Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, Minnesota, United States of America, 2 Surgery, University of Minnesota, Minneapolis, Minnesota, United States of America, 3 Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

* kanna001@umn.edu

Abstract

Airway smooth muscle (ASM) cells play a critical role in the pathophysiology of asthma due to their hypercontractility and their ability to proliferate and secrete inflammatory mediators. microRNAs (miRNAs) are gene regulators that control many signaling pathways and thus serve as potential therapeutic alternatives for many diseases. We have previously shown that miR-708 and miR-140-3p regulate the MAPK and PI3K signaling pathways in human ASM (HASM) cells following TNF-α exposure. In this study, we investigated the regulatory effect of these miRNAs on other asthma-related genes. Microarray analysis using the Illumina platform was performed with total RNA extracted from miR-708 (or control miR)-transfected HASM cells. Inhibition of candidate inflammation-associated gene expression was further validated by qPCR and ELISA. The most significant biologic functions for the differentially expressed gene set included decreased inflammatory response, cytokine expression and signaling. qPCR revealed inhibition of expression of CCL11, CXCL10, CCL2 and CXCL8, while the release of CCL11 was inhibited in miR-708-transfected cells. Transfection of cells with miR-140-3p resulted in inhibition of expression of CCL11, CXCL12, CXCL10, CCL5 and CXCL8 and of TNF-α-induced CXCL12 release. In addition, expression of RARRES2, CD44 and ADAM33, genes known to contribute to the pathophysiology of asthma, were found to be inhibited in miR-708-transfected cells. These results demonstrate that miR-708 and miR-140-3p exert distinct effects on inflammation-associated gene expression and biological function of ASM cells. Targeting these miRNA networks may provide a novel therapeutic mechanism to down-regulate airway inflammation and ASM proliferation in asthma.

Introduction

Several recent reports have provided evidence that airway smooth muscle (ASM) has strong pro-inflammatory and immunomodulatory functions [1–4]. These properties of ASM are mediated through its synthetic function as well as through expression of a variety of cell-surface molecules, integrins [5–7], and Toll-like receptors [8, 9]. During acute airway inflammation,
mediators and cytokines released from structural and inflammatory cells alter ASM contractile function [10–13]. However, during persistent airway inflammation, cytokines and chemokines produced by inflammatory cells and ASM can cause ASM proliferation, leading to structural changes in the airways, often referred to as airway remodeling [14, 15]. During chronic airway inflammation, the immunomodulatory role of ASM may be more significant in establishing structural changes within the airways than its contractile function. In this context, recent reports show that ASM is capable of releasing cytokines such as IL-5 [16, 17], IL-6 [18, 19], IL-33 [20], TSLP [21], GM-CSF [22] and VEGF [23]; chemokines such as RANTES [16], Fractalkine [24], CCL11 [25], CXCL10 [26–28], CXCL8 [29]; adhesion molecules such as ICAM-1 [30, 31], VCAM-1 [30, 32], CD44 [33] and LFA-1 [34]; and growth factors such as IGF-1 [35, 36] and stem cell factor [37]. Cytokines released by immune cells recruited into the lungs during allergic inflammation may also stimulate ASM cells to alter the expression of proinflammatory genes in an autocrine or paracrine manner. There is also evidence for hypersecretion of chemokines both constitutively and in response to cytokines in ASM cells obtained from asthmatics than in cells from non-asthmatics [14, 38]. There is also increased chemotaxis of mast cells toward ASM cells from asthmatics both in vivo and in vitro [28, 39–41]. Other studies have examined the transcriptional regulation of expression of chemokine genes in human ASM cells (HASM) [29, 42]. While such transcriptional regulation of expression of chemokines is better understood, the post-transcriptional regulation is an emerging area of investigation. In this context, recent studies provide evidence for specific microRNAs in the regulation of ASM proliferation [43, 44], ASM phenotype [45] and airway inflammation [46, 47].

microRNAs (miRNAs) are small non-coding ~22nt RNAs that regulate gene expression by binding to the 3’-Untranslated Region (3’UTR) of target mRNAs to cause mRNA degradation and/or translational repression [48]. Since binding of miRNAs to target sequences is dependent on its ‘seed’ sequence, a single miRNA can potentially regulate a large number of genes. Specific miRNAs have already been discovered that regulate cellular functions such as differentiation, proliferation, and apoptosis. [48–50] Dysregulation of mRNA expression has been implicated in airway inflammation [48–50], but the specific miRNAs (miR-140-3p and miR-708) controlling inflammation have not previously been reported. In a recent report we identified miR-708 in the post-transcriptional regulation of expression of a cell-surface protein CD38 through two major signaling pathways [51]. Transfection of HASM cells with miR-708 causes the induction of phosphatase and tensin homolog (PTEN), which regulates PI3K/AKT signaling by decreasing Akt phosphorylation and interacts with members of the NF-κB signaling network. miR-708 also induces DUSP-1, a dual specificity phosphatase, leading to JNK MAPK dephosphorylation [51].

Our recent investigations also provided evidence for down-regulation of p38 MAP kinase and NF-κB activation in HASM cells following transfection with miR-140-3p [52]. The net effect of PTEN and DUSP-1 induction as well as inhibition of MAP kinase and NF-κB activation in ASM cells by miRNAs should lead to modulation of key signaling pathways involved in inflammation and cell proliferation. There is evidence that the expression of several chemokine genes, the release of chemokines and cell proliferation in HASM cells are also regulated by these same signaling pathways [53–59].

In this study, we evaluated differentially expressed genes using microarrays and qPCR in HASM cells following miR-708 transfection and stimulation with the inflammatory cytokine TNF-α, with particular emphasis on the expression of cytokine/chemokine genes, other pro-inflammatory genes, and those reported to be involved in the asthmatic phenotype. Since many of these chemokines are involved in the recruitment of inflammatory cells such as eosinophils, basophils, mast cells and T lymphocytes into the airways during allergic airway disease, we measured their release from cells stimulated with the inflammatory cytokine TNF-α and following transfection with miR-708 or miR-140-3p.
Materials and Methods

Ethics statement: Airway smooth muscle cells from human lungs were prepared in Dr. Panettieri’s laboratory at the University of Pennsylvania. Lung tissues were obtained from the National Disease Resource Interchange (NDRI) and its use was approved by the Institutional Review Board at the University of Pennsylvania and University of Minnesota. All donor tissue is harvested anonymously and de-identified and therefore the use of the cells does not constitute human subjects research. Primary ASM cells were isolated from deceased donors.

Reagents

Reagents used in the current study: DMEM from GIBCO-BRL (Grand Island, NY); rh-TNF-α from R&D Systems (Minneapolis, MN); TRIzol, SuperScript III reverse transcriptase, Opti-MEM® reduced serum medium and Lipofectamine® RNAiMax transfection reagent from Invitrogen Life Technologies (Carlsbad, CA); Brilliant III Ultra-Fast SYBR Green qPCR Master Mix from Agilent Technologies Inc (Santa Clara CA); control oligo (scrambled sequence mimic) and miR-708 mimic (mature miR-708 sequence: 5’-AAGGAGCUUACAAUCUAGCUGGG-3’; mature miR-140-3p sequence: 5’-UACCACAGGGUAGAACCAGG-3’) from Dharmacon (LaFayette, CO); Tris-base, glucose, HEPES and other chemicals from Sigma Chemical Co. (St. Louis, MO).

Microarray sample preparation

ASM cells, derived from three de-identified healthy donors, used between 2-5th passages, were seeded at 1.5 X 10⁵ cells/well and transfected with mimic or scrambled sequence mimic of miR-708 at 50 nM concentration [51]. We used the same concentration which was previously determined to be optimal to inhibit the expression of CD38 [51]. Cells that were growth arrested (24 h) after transfection, were induced with pro-inflammatory cytokines TNF-α at 10 ng/ml (24 h). Total RNA was harvested using PureLink RNA isolation kit according to the manufacturer’s instructions. Purity of the RNA was determined with a Nanometer 2000C for the ratios 260/280 and 260/230. For each condition (mimic or scrambled oligo treatment), 1000 ng of total RNA was subjected to microarray analysis. Genome-wide changes in gene expression in transfected cells were generated using Illumina human (HT-12) arrays and analyzed using BeadStudio version 3.1.1.

Data Analysis

For statistical analysis and clustering, we used the Partek Genomics Suite software package (Partek Inc., St. Louis, MO, USA). We performed a paired t-test with donor ID and mimic/control as the nominal variables. Before comparison analysis and clustering, we filtered extremely low and non-variant genes out of the datasets. Significance cutoff filters were set at P < 0.05 and an expression change of at least 2-fold. For functional and pathway analyses we used Ingenuity Pathway Analysis (IPA) software (Qiagen, Redwood City, CA, USA). IPA employs a right-tailed Fisher exact test to calculate a P value corresponding to the probability that a biological function not relevant to the input dataset is falsely identified as relevant. A Benjamini–Hochberg false discovery rate of 0.05 was used to correct such P values.

Validation of genes by qPCR

As described in the “Microarray sample preparation”, total RNA was isolated and cDNA was prepared using reverse transcription kit from Invitrogen Life Technologies (Carlsbad, CA). cDNAs were subjected to qPCR analysis using Brilliant SYBR Green Master Mix and
Stratagene Mx3000p qPCR system (Foster City, California, 94404). Primer sequences and conditions for the genes tested are provided in Table 1. The β-actin gene was used as a housekeeping gene to normalize the expressions of other genes.

**Chemokine Release assay**

HASM cells were transfected with mimic or scrambled sequence mimic of miR-708 or miR-140-3p or were untransfected (control) as described in earlier publications [51, 52]. Cells were then growth arrested and treated with 10ng/ml TNF-α. Cell culture supernatants were collected at different time points ranging from 6–48 h. Collected supernatants were aliquoted and immediately stored at -80°C until assayed. Chemokines in the culture supernatants were quantified using ELISA kits from R&D system (Minneapolis, MN) according to the manufacturer’s instructions.

**Results**

**Microarray results**

We performed a detailed analysis of the pattern of gene expression in HASM cells stimulated with TNF-α following transfection with miR-708. Gene expression results are shown as a heatmap (Fig 1). Visual inspection easily identifies differential patterns of expression between samples treated with a miR-708-5p mimic (purple bar) versus a scrambled control (orange bar). Principal Component Analysis (PCA) confirmed the mimic as the primary differential component (Fig 2). Our analysis found that 821 genes were differentially expressed (348 upregulated and 473 downregulated) in HASM cells transfected with a miR-708 mimic versus a scrambled control sequence (paired t-test, P < 0.05). Table 2 summarizes the differentially expressed chemokines/cytokines, transcription factors, extracellular matrix components, calcium signaling...

---

Table 1. Primer Sequences.

| Gene   | primer sequences             |
|--------|------------------------------|
| CXCL10 | F: 5’-3’ GAACTGTACGCTGTACCTGCA  |
|        | R: 5’-3’ TGATGACCCTTCGATTCTGGA |
| CXCL8  | F: 5’-3’ ACTGAGAGTGAGTGAAGTGGCA |
|        | R: 5’-3’ AGCCCTCTGC ACCAGTTTTTC |
| CCL5   | F: 5’-3’ CATGTCCTTTGTCCACCGA |
|        | R: 5’-3’ TCCAAAGCTAGGACAAGGCA |
| CCL2   | F: 5’-3’ AGTGTACGCTGGGCATGGAT |
|        | R: 5’-3’ GCCCTCAGC ATGAAATGTC |
| CXCL12 | F: 5’-3’ TGCAGAGGCCAACTGCAAG |
|        | R: 5’-3’ CAGCCGGGCTACAATCTGAA |
| CCL11  | F: 5’-3’ GCCAGAAGCTGTTGACCTCA |
|        | R: 5’-3’ GGAGTTGGAGATTTTTGGTCCAGAT |
| RARRES2| F: 5’-3’ GAGGAACCTGGAGAAACCCG |
|        | R: 5’-3’ CATGGCTGGGAGTGAAGCGG |
| ADAM33 | F: 5’-3’ GACCTAAGATGGTGTGCCAGA |
|        | R: 5’-3’ AGCCTGGC TTGCTCACAAGA |
| CD44   | F: 5’-3’ AGATCGTGGATTGACGCTG |
|        | R: 5’-3’ GTCCACATTCGACGATTC |
| β-Actin| F: 5’-3’ ACCTGTGCCCATCTACGAGG |
|        | R: 5’-3’ AGGGGCGGCCACTGTCATACT |

doi:10.1371/journal.pone.0150842.t001
molecules, growth factors and other genes related to airway hyperresponsiveness. The complete list of genes is available as S1 Data.

Functional and Pathway Analysis

The most significant biologic functions for this differential gene set included decreased inflammatory response, cytokine expression and signaling. In particular, many components of the IL-17 pro-inflammatory pathway were down-regulated. Multiple pathways and biologic functions related to cell cycle progression were predicted to be upregulated.

miR-708 inhibits chemokine mRNA expression and other asthma related genes

Results of gene expression analysis revealed significant down-regulation of expression of several chemokine genes as well as some genes associated with the asthmatic phenotype (Fig 3). Therefore, we used qPCR analysis to validate the microarray results of expression of these genes. HASM cells were transfected with miR-708-5p mimic oligonucleotides or the scrambled control and then treated with TNF-\(\alpha\). 24 hours following the addition of TNF-\(\alpha\), total RNA was collected from the cells and subjected to qPCR analysis. There was significant inhibition in the expression of chemokine genes CCL11 (\(P <0.0001\)), CXCL10 (\(P =0.0308\)), CCL2 (\(P =0.0422\)) and CXCL8 (\(p =0.0156\)) (Fig 4) as well as other ‘asthma related’ genes such as CD44 (\(P =0.0328\)), ADAM33 (\(P =0.0016\)) and RARRESS2 (\(P =0.0006\)) (Fig 5). On the other hand, the mRNA expression levels for chemokine genes CCL5 (\(P =0.0549\)) and CXCL12 following transfection with the miR-708 mimic were not significantly different from expression in scrambled oligonucleotide-transfected cells (Fig 4).

miR-708 transfection and release of chemokines

To determine whether changes in the mRNA expression of chemokines were reflected in their protein expression, we measured their release in HASM cell culture supernatant following miR-708 mimic or scrambled sequence mimic transfection and TNF-\(\alpha\) induction. As a control, we collected the culture supernatant from untransfected but TNF-\(\alpha\) treated HASM cells. Of the
chemokines that were assayed, only CCL11 release exhibited significant downregulation of release in mimic miR-708-transfected cells compared to release from cells transfected with the scrambled oligonucleotide or from control cells at all time points examined (Fig 6).

miR-140-3p transfection and chemokine mRNA expression and release

The expression of many of the chemokine genes in HASM cells is regulated by signaling pathways that are downregulated by miR-140-3p. Therefore, we measured the expression and release of chemokines in response to TNF-α following miR-140-3p transfection. HASM cells were transfected with miR-140-3p mimic oligonucleotides or the scrambled control and then
### Table 2. Differentially expressed genes in TNF-α-stimulated HASM cells following miR-708 mimic transfection.

| Gene ID   | Fold change | Function                                                                 |
|-----------|-------------|--------------------------------------------------------------------------|
| **Inflammatory mediators** |             |                                                                          |
| Chemokines |             |                                                                          |
| CXCL10    | -2.695      | Chemoattracts mast cell                                                  |
| CCL8      | -5.38       | Chemoattracts monocytes                                                  |
| CCL11     | -8.968      | Chemoattracts Eosinophils                                               |
| CXCL12    | -5.254      | Chemoattractant T-lymphocytes & monocytes                               |
| CCL5      | -3.52       | Chemoattracts Eosinophil                                                |
| CCL2      | -3.21       | Chemoattracts monocytes, fibrocytes and basophils                        |
| CXCL8     | -2.03       | Chemoattracts neutrophils, basophils and T-cells                        |
| CXCL16    | -2.688      | Scavenger receptor on macrophages                                        |
| CXCL5     | -2.389      | Activates neutrophils                                                   |
| CXCL9     | -2.375      | Chemoattracts activated T-cells                                          |
| CXCL11    | -2.151      | Chemoattracts interleukin-activated T-cells                              |
| CXCL6     | -2.039      | Chemoattracts neutrophil, granulocytes                                   |
| Cytokines |             |                                                                          |
| IL18BP    | -4.028      | Inhibits the early TH1 cytokine response                                 |
| IL6       | -1.832      | Stimulates the differentiation of B-cells and acts as a myokine.         |
| TNFSF13B  | -4.216      | Stimulates B- and T-cell function                                        |
| Genes associated with Extracellular Matrix |             |                                                                          |
| VCAM1     | -20.59      | Enhances leukocyte-endothelial cell adhesion and T cell inflammatory functions |
| COL3A1    | -9.608      | Activates RhoA pathway                                                  |
| COL5A1    | -3.185      | A major structural component of microfibrils                            |
| CD44      | -4.25       | Increases airway hyperresponsiveness [80]; leads to inflammation [61, 81] by interacting with T-cell [33] and mast cell [67]; increases ASM cell proliferation [82] |
| THBS1     | -4.797      | Increases IL-8 production [83]                                           |
| MXRA5     | -4.581      | Associates with matrix-remodeling protein                               |
| ADAMTS-1  | 6.158       | Increases FEV1 [84]                                                      |
| TAPBP     | -4.38       | Increases antigen processing and assembly of MHC class I [85]           |
| Transcription factors |             |                                                                          |
| NFKB1     | -1.876      | Regulates immune response                                               |
| RELA      | -1.728      | Regulates immune response                                               |
| Calcium signaling |             |                                                                          |
| CD38      | -2.286      | Increases cell adhesion, signal transduction, AHR and calcium signaling. |
| BDKRB1    | -1.994      | Increases chronic and acute inflammatory responses                       |
| FKBP10    | -2.198      | Regulates [Ca2+]i dynamics                                               |
| Growth factors and related genes |             |                                                                          |
| IGFBP5    | -4.009      | Prolongs the half-life of the IGFs                                       |
| PDGFRL    | -4.258      | Increases proliferation                                                 |
| EGFL6     | -3.886      | Regulates cell cycle & induces proliferation                             |
| Airway hyper-responsiveness |             |                                                                          |
| ACTG2     | -17.181     | Increases muscle contraction                                             |
| TAGLN     | -4.691      | Increases calcium interactions and contractility                         |
| MLK       | -2.12       | Increases Smooth muscle contraction                                      |
| PDE5A     | -2.50       | Inactivates cGMP [86]                                                    |
| Genes associated with proliferation |             |                                                                          |
| F2F7      | 6.8         | Anti-proliferative [87]                                                  |

(Continued)
treated with TNF-α. Twenty four hours following the addition of TNF-α, total RNA was collected from the cells and subjected to qPCR analysis. There was significant inhibition in the expression of chemokine genes CCL11 \( (p < 0.005) \), CXCL12 \( (p < 0.0001) \), CCL5 \( (p < 0.0009) \), CXCL10 \( (p = 0.0033) \), CCL2 \( (p = 0.0422) \) and CXCL8 \( (p = 0.0033) \) (Fig 7). We measured the...

Table 2. (Continued)

| Inflammatory mediators | Gene ID | Fold change | Function                                      |
|------------------------|---------|-------------|-----------------------------------------------|
| IL24                   | 11.6    | Anti-proliferative [88] |
| COL1A1                 | -7.474  | Increases ASM cell proliferation [89] |
| DUSP6                  | 10.915  | Decreases ASM cell proliferation |
| UBE2C                  | 18.96   | Increases cell proliferation |
| CDC20                  | 16.459  | Increases cell proliferation |
| ID1                    | 16.089  | Increases cell proliferation |
| ANGPTL4                | 12.633  | Increases ASM cell proliferation [90] |
| CDK1                   | 5.387   | Increases cell proliferation |

doi:10.1371/journal.pone.0150842.t002

Fig 3. Network diagram. Potential regulatory pathways connecting miR-708 and down-regulated molecules of interest in HASM cells. Several chemokine genes were observed to be significantly down-regulated, particularly CD44 and CD38 (-3.23 and -2.287, respectively). Nodes are colored either by observed expression changes in the paired t-test (Green) or by predicted activation status (Blue = predicted inhibition) based on the assumption of increased miR-708-5p (Red). Potential relationships are indicated by solid (direct interaction) or dotted (indirect interaction) lines. Interaction lines are colored based on whether the predicted relationship leads to inhibition (Blue), leads to predicted activation (Yellow; but inconsistent with observed results), or effect was not able to be predicted (Gray).

doi:10.1371/journal.pone.0150842.g003
release of chemokines in HASM cell culture supernatant following miR-140-30 mimic or scrambled sequence mimic transfection and TNF-α induction. As a control, we collected the culture supernatant from untransfected but TNF-α-treated HASM cells. Of the chemokines that were assayed, only CXCL12 release exhibited significant down-regulation of release in mimic miR-140-3p-transfected cells compared to release from cells transfected with the scrambled miR-140-3p oligonucleotides or from control cells at all time points examined (Fig 7).

Discussion

Using a transcriptomics-based approach, we investigated differentially expressed genes in HASM cells treated with TNF-α following miR-708 transfection compared to expression in cells transfected with the scrambled mimic oligonucleotides. This analysis revealed changes in

![Fig 4. Downregulation of chemokine mRNA expression following miR-708 transfection.](image)

![Fig 5. Down regulation of other ‘asthma related’ genes by miR-708.](image)
the expression of several genes, including those for chemokines/cytokines, extracellular matrix proteins, transcription factors, calcium signaling molecules, growth factors, and genes associated with airway hyperresponsiveness. Several genes involved in cell cycle regulation were upregulated, although the genes that block cell proliferation such as E2F7, DUSP6 and IL-24, were also significantly upregulated. There was downregulation of expression of JNK MAP kinase which is involved in serum-induced ASM cell proliferation [60]. The changes in the expression of chemokine genes revealed in this approach were confirmed by qPCR. In addition, miR-708 also caused downregulation of expression of several ‘asthma-related’ genes such as CD44 [33, 61], ADAM33 [62, 63] and RARRES2 [64–66]. Prior reports have shown that CD44 is involved in mast cell-ASM cell adherence through Type I collagen and this adherence is greater during airway inflammation as well as in ASM cells derived from asthmatics [67]. miR-140-3p transfection of HASM cells also resulted in inhibition of expression of chemokines that were sensitive to inhibition by miR-708, with the exception of CXCL12. However, chemokine release measurements revealed inhibition of release of CXCL12, but not the other chemokines.

In the present study, we examined the post-transcriptional regulation of expression of several inflammatory genes in HASM cells by miR-708. HASM cells express miR-708 and miR-140-3p constitutively and TNF-α causes a significant reduction in their expression [51, 52]. Furthermore, the constitutive expression of DUSP-1 and PTEN are also significantly downregulated following exposure to TNF-α [51]. Transfection with miR-708 in cells stimulated with TNF-α resulted in a significant augmentation of PTEN and DUSP-1 expression, with concomitant decreased activation of Akt and JNK MAP kinase, respectively [51]. The PI3 kinase/Akt and MAP kinase signaling mechanisms are involved in airway inflammation by activating transcription factors such as NF-κB and AP-1 [68–71]. Recent reports have shown that this signaling is involved in the hyperproliferative phenotype of ASM cells from asthmatics [54]. Our earlier study showed that miR-140-3p decreases the activation of p38 MAP kinase and NF-κB in

![Fig 6. Chemokine release from HASM cells following miR-708 transfection.](https://example.com/fig6.png)

HASM cells from 3–6 donors were transfected with mimic or scrambled sequence mimic of miR-708 and treated with TNF-α (10ng/ml) following growth arrest of cells. Untransfected cells treated with TNF-α served as an additional control. Twenty hours later cell culture supernatants were collected for the measurement of chemokines. Note the release of CCL11 was significantly inhibited at every time point following miR-708 transfection when compared to scrambled sequence mimic transfection. Data represents mean±SEM. doi:10.1371/journal.pone.0150842.g006
HASM cells. The promoter regions of several chemokine genes contain binding sites for NF-κB and AP-1 as well as for other transcription factors [72–74]. Furthermore, TNF-α has been shown to induce the expression and release of cytokines/chemokines from HASM cells [25, 41, 42, 75, 76] including the chemokines that we have examined in this study. Although the mechanisms by which miR-708 decreased the expression of the chemokine genes that we examined are not addressed in this study, the 3′UTRs of CXCL12 and CCL5 have predicted target sites for miR-708 indicating that this miRNA may directly target these transcripts. As well, miR-140-3p also has predicted binding sites at 3′UTR of CXCL12 and CXCL8. It is very likely that the inhibition of expression of chemokine genes following miR-708 or miR-140-3p transfection resulted from indirect mechanisms of decreased activation of transcription factors and MAP kinases as well as binding of miRNAs to cause translational repression and/or mRNA breakdown.

The miRNAs examined in this study had profound inhibitory effects on the chemokines involved in the recruitment of eosinophils, mast cells, T lymphocytes and fibrocytes. Chemokine release studies additionally revealed inhibition of release of CCL11 and CXCL12. It is interesting to note that our microarray results showed a high level of downregulation of CXCL12 expression by miR-708, while the qPCR results did not show any change in CXCL12 transcript levels following miRNA transfection. It is very likely that miR-708 may regulate transcription and release of some chemokines while it may have a dominant effect on release.
for others. It is also known that production of specific chemokines in ASM cells may involve
unique signaling pathways and stimuli, as has been shown for CXCL10 release [41]. In this
study, it was reported that in HASM cells exposed to TNF-α or IL-1β, CXCL10 production
required JNK MAP kinase activation, while its release was induced by p38 MAP kinase activa-
tion. The results of the microarray analysis of differentially expressed genes and qPCR results
confirmed selective downregulation of JNK MAP kinase expression by miR-708, with
decreased JNK MAP kinase phosphorylation. This decreased JNK MAP kinase activation may
be a mechanism involved in the inhibition of CCL11 release and expression in miR-708 trans-
fected cells following exposure to TNF-α. It should be noted that among the chemokine tran-
scripts examined, miR-708 transfection resulted in a profound inhibition of CCL11 expression
while the inhibition of expression of other chemokine transcripts was modest and not of suffi-
cient magnitude to be reflected in inhibition of release. Transfection of cells with miR-140-3p
casused significant attenuation of expression of all the five chemokine genes examined, while
exerting a selective inhibitory effect on the release of CXCL12 but not the other chemokines.
The decreased p38 MAP kinase activation following miR-140-3p transfection noted in our pre-
vious studies [59] may be involved in the attenuation of CXCL12 release in response to TNF-α.
Furthermore, these miRNAs may selectively inhibit the release of some chemokines but not
others. Recent investigations have shown that stimulation of ASM cells with a mixture of cyto-
kines causes significantly higher amounts of chemokine release than following exposure to
individual cytokines [56, 59]. It should be emphasized that in our study chemokine release was
measured from cells following miRNA transfection and growth-arrest, before stimulation with
TNF-α. It will be interesting to examine release of chemokines in response to a mixture of cyto-
kines following miRNA transfection.

In conclusion, this study demonstrates a profound anti-inflammatory effect of miR-708 and
miR-140-3p in HASM cells stimulated with the inflammatory cytokine TNF-α. Specifically,
targeting these miRNAs resulted in the down-regulation of expression of multiple different
chemokines and the release of specific chemokines involved in the recruitment of inflamma-
tory cells into the airways during allergic airway inflammation. Previous results have shown
that CD38, involved in generating calcium mobilizing molecules, contributes to airway hyper-
responsiveness. [77–79]. Therapeutic strategies that target both CD38 and these miRNA net-
works may prove effective in reversal of allergen-induced changes in airway
hyperresponsiveness and airway inflammation, particularly in the asthmatic patient.

Supporting Information

S1 Data. Complete list of differentially expressed genes in HASM cells transfected with a
miR-708 mimic. Table shows fold-change in expression relative to expression in cells trans-
fected with a scrambled control sequence and the p value.

Author Contributions

Conceived and designed the experiments: MD AES SR RAP SS MSK. Performed the experi-
ments: MD AES. Analyzed the data: MD AES SR SS MSK. Contributed reagents/materials/
analysis tools: RAP SS MSK. Wrote the paper: MD AES SR SS MSK.

References

1. Damera G, Panettieri RA Jr. Does airway smooth muscle express an inflammatory phenotype in
asthma? British journal of pharmacology. 2011; 163(1):68–80. Epub 2010/12/24. doi: 10.1111/j.1476-
5381.2010.01165.x PMID: 21175578; PubMed Central PMCID: PMC3085869.
2. Hershenson MB, Brown M, Camoretti-Mercado B, Solway J. Airway smooth muscle in asthma. Annu Rev Pathol. 2008; 3:523–55. PMID: 18039134

3. Dekkers BG, Maarsingh H, Meurs H, Gosens R. Airway structural components drive airway smooth muscle remodeling in asthma. Proc Am Thorac Soc. 2009; 6(8):683–92. Epub 2009/12/17. doi: 10.1513/pats.200907-056PD PMID: 20008876.

4. Tliba O, Panettieri RA Jr. Noncontractile functions of airway smooth muscle cells in asthma. Annu Rev Physiol. 2009; 71:509–35. Epub 2008/10/15. doi: 10.1146/annurev.physiol.010908.163227 PMID: 18851708.

5. Gunst SJ, Tang DD. The contractile apparatus and mechanical properties of airway smooth muscle. Eur Respir J. 2000; 15(3):600–16. Epub 2000/04/12. PMID: 10759460.

6. Tatler AL, John AE, Jolly L, Habgood A, Porte J, Brightling C, et al. Integrin alphavbeta5-mediated TGF-beta activation by airway smooth muscle cells in asthma. Journal of immunology. 2011; 187 (11):6094–107. Epub 2011/10/26. doi: 10.4049/jimmunol.1003507 PMID: 22025551; PubMed Central PMCID: PMC3242066.

7. Gong H, Shen B, Flevaris P, Chow C, Lam SC, Voyno-Yasenetskaya TA, et al. G protein subunit Galpha13 binds to integrin alphabeta3 and mediates integrin "outside-in" signaling. Science. 2010; 327 (5963):340–3. Epub 2010/01/16. doi: 10.1126/science.1174779 PMID: 20075254; PubMed Central PMCID: PMC2842917.

8. Ekman AK, Adner M, Cardell LO. Toll-like receptor 7 activation reduces the contractile response of airway smooth muscle. Eur J Pharmacol. 2011; 652(1–3):145–51. Epub 2010/12/02. doi: 10.1016/j.ejphar.2010.11.009 PMID: 2118677.

9. Manetsch M, Seidel P, Heintz U, Che W, Hughes JM, Ge Q, et al. TLR2 ligand engagement upregulates airway smooth muscle TNFalpha-induced cytokine production. American journal of physiology Lung cellular and molecular physiology. 2012; 302(9):L838–45. Epub 2012/01/17. doi: 10.1152/ajplung.00317.2011 PMID: 22249999.

10. Perez-Zoghbi JF, Sanderson MJ. Endothelin-induced contraction of bronchiole and pulmonary arteriole smooth muscle cells is regulated by intracellular Ca2+ oscillations and Ca2+ sensitization. American journal of physiology Lung cellular and molecular physiology. 2007; 293(4):L1000–6. Epub 2007/07/10. doi: 10.1152/ajplung.00184.2007 PMID: 17616645.

11. Xu J, Zhong NS. Mechanisms of bronchial hyperresponsiveness: the interaction of endothelin-1 and other cytokines. Respirology. 1999; 4(4):413–7. Epub 1999/12/28. PMID: 10612578.

12. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. The Journal of allergy and clinical immunology. 2006; 118(3):551–9; quiz 60–1. Epub 2006/09/05. doi: 10.1016/j.jaci.2006.07.012 PMID: 16950269.

13. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. The Journal of experimental medicine. 1995; 181(4):1373–80. Epub 1995/04/01. PMID: 7535336; PubMed Central PMCID: PMC2191950.

14. Haliwani R, Al-Abri J, Beland M, Al-Jahdali H, Halayko AJ, Lee TH, et al. CC and CXC chemokines induce airway smooth muscle cell proliferation and survival. Journal of immunology. 2011; 186(7):4156–63. Epub 2011/03/04. doi: 10.4049/jimmunol.1001210 PMID: 21368236.

15. Khan MA. Inflammation signals airway smooth muscle cell proliferation in asthma pathogenesis. Multidiscip Respir Med. 2013; 8(1):11. Epub 2013/02/08. doi: 10.1186/2049-6958-8-11 PMID: 23388501; PubMed Central PMCID: PMC3568740.

16. John H, Hirst SJ, Jose PJ, Robichaud A, Berkman N, Witt C, et al. Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: regulation by T helper 2 cytokines and corticosteroids. Journal of immunology. 1997; 158(4):1841–7. Epub 1997/02/15. PMID: 9029124.

17. Lazzari N, Belvisi MG, Patel HJ, Chung KF, Yacoub MH, Mitchell JA. RANTES release by human airway smooth muscle: effects of prostaglandin E2 and fenoterol. Eur J Pharmacol. 2001; 433(2–3):231–5. Epub 2002/01/05. PMID: 11755157.

18. McKay S, Hirst SJ, Haas MB, de Jongste JC, Hoogsteden HC, Saxena PR, et al. Tumor necrosis factor-alpha enhances mRNA expression and secretion of interleukin-6 in cultured human airway smooth muscle cells. American journal of respiratory cell and molecular biology. 2000; 23(1):103–11. Epub 2000/06/29. doi: 10.1165/ajrccm.23.1.3765 PMID: 10873159.

19. Ammit AJ, Hoffman RK, Amrani Y, Lazaar AL, Hay DW, Torphy TJ, et al. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells. Modulation by cyclic adenosine monophosphate. American journal of respiratory cell and molecular biology. 2000; 23(6):794–802. Epub 2000/12/06. doi: 10.1165/ajrccm.23.6.4184 PMID: 11104733.

20. Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. Journal of immunology. 2009; 183(8):5094–103.
21. Zhang K, Shan L, Rahman MS, Unruh H, Halayko AJ, Gourni AS. Constitutive and inducible thymal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. American journal of physiology Lung cellular and molecular physiology. 2007; 293(2):L375–82. Epub 2007/05/22. doi: 10.1152/ajplung.00045.2007 PMID: 17513456.

22. Saunders MA, Mitchell JA, Seldon PM, Yacoub MH, Barnes PJ, Giembycz MA, et al. Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. British journal of pharmacology. 1997; 120(4):545–6. Epub 1997/02/01. doi: 10.1038/sj.bjp.0700998; PubMed Central PMCID: PMC1564521.

23. Knox AJ, Corbett L, Stocks J, Holland E, Zhu YM, Pang L. Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2001; 15(13):2480–8. Epub 2001/11/02. doi: 10.1096/fj.01-0296com PMID: 11699473.

24. El-Shazly A, Berger P, Girotot PO, Ousova O, Fayon M, Vernejoux JM, et al. Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma. Journal of immunology. 2006; 176(3):1860–8. Epub 2006/01/21. PMID: 16424217.

25. Ghaffar O, Hamid Q, Renzi PM, Allakhverdi Z, Melet S, Hogg JC, et al. Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells. American journal of respiratory and critical care medicine. 1999; 159(6):1933–42. PMID: 10351942.

26. Gao YD, Cao J, Li P, Huang G, Yang J. Th2 cytokine-primed airway smooth muscle cells induce mast cell chemotaxis via secretion of ATP. J Asthma. 2014; 51(10):997–1003. Epub 2014/10/02. doi: 10.3109/02770903.2014.939283 PMID: 25272186.

27. Alkhouri H, Cha V, Tong K, Moir LM, Armour CL, Hughes JM. Human Lung Mast Cell Products Regulate Airway Smooth Muscle CXCL10 Levels. J Allergy (Cairo). 2014; 2014:875105. Epub 2014/03/22. doi: 10.1155/2014/875105 PMID: 24648846; PubMed Central PMCID: PMC3933032.

28. Brightling CE, Ammit AJ, Kaur D, Black JL, Wardlaw AJ, Hughes JM, et al. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. American journal of respiratory and critical care medicine. 2005; 171(10):1103–8. Epub 2005/05/10. doi: 10.1164/rcrm.200409-1220OC PMID: 15879427.

29. John AE, Zhu YM, Brightling CE, Pang L, Knox AJ. Human airway smooth muscle cells from asthmatic individuals have CXCL8 hypersecretion due to increased NF-kappa B p65, C/EBP beta, and RNA polymerase II binding to the CXCL8 promoter. Journal of immunology. 2009; 183(7):4682–92. Epub 2009/09/08. doi: 10.4049/jimmunol.0803832 PMID: 19734226; PubMed Central PMCID: PMC3992371.

30. Panettieri RA Jr, Lazaar AL, Pure E, Albelda SM. Activation of cAMP-dependent pathways in human airway smooth muscle cells inhibits TNF-alpha-induced ICAM-1 and VCAM-1 expression and T lymphocyte adhesion. Journal of immunology. 1995; 154(5):2358–65. Epub 1995/03/01. PMID: 7532667.

31. Amrani Y, Lazaar AL, Panettieri RA Jr. Up-regulation of ICAM-1 by cytokines in human tracheal smooth muscle cells involves an NF-kappa B-dependent signaling pathway that is only partially sensitive to dexamethasone. Journal of immunology. 1999; 163(4):2128–34. Epub 1999/08/10. PMID: 10438953.

32. Lazaar AL, Krymskaya VP, Das SK. VCAM-1 activates phosphatidylinositol 3-kinase and induces p120Cbl phosphorylation in human airway smooth muscle cells. Journal of immunology. 2001; 166(1):155–61. Epub 2000/12/21. PMID: 11123288.

33. Lazaar AL, Albelda SM, Pilewski JM, Brennan B, Pure E, Panettieri RA Jr. T lymphocytes adhere to airway smooth muscle cells via integrins and CD44 and induce smooth muscle cell DNA synthesis. The Journal of experimental medicine. 1994; 180(3):807–16. Epub 1994/09/01. PMID: 7520473; PubMed Central PMCID: PMC2191654.

34. Grunstein MM, Hakonarson H, Maskeri N, Kim C, Chuang S. Intrinsic ICAM-1/LFA-1 activation mediates altered responsiveness of atopic asthmatic airway smooth muscle. American journal of physiology Lung cellular and molecular physiology. 2000; 278(6):L1154–63. Epub 2000/06/03. PMID: 10835320.

35. Rajah R, Nachajon RV, Collins MH, Hakonarson H, Grunstein MM, Cohen P. Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. American journal of respiratory and molecular biology. 1999; 20(2):199–208. Epub 1999/01/28. doi: 10.1165/ajrccm.20.2.3148 PMID: 9922210.

36. Noveral JP, Bhala A, Hintz RL, Grunstein MM, Cohen P. Insulin-like growth factor axis in airway smooth muscle cells. The American journal of physiology. 1994; 267(6 Pt 1):L761–5. Epub 1994/12/01. PMID: 7528983.

37. Hollins F, Kaur D, Yang W, Cruse G, Saunders R, Sutcliffe A, et al. Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: cooperative roles for CADM1, stem cell factor, and IL-6. Journal of immunology. 2008; 181(4):2772–80. Epub 2008/08/08. PMID: 18684968; PubMed Central PMCID: PMC3992374.
38. Singh SR, Sutcliffe A, Kaur D, Gupta S, Desai D, Saunders R, et al. CCL2 release by airway smooth muscle is increased in asthma and promotes fibrocyte migration. Allergy. 2014; 69(9):1189–97. Epub 2014/06/17. doi: 10.1111/all.12444 PMID: 24931417; PubMed Central PMCID: PMC4215601.

39. Ozier A, Allard B, Bara I, Girodet PO, Trian T, Marthan R, et al. The pivotal role of airway smooth muscle in asthma pathophysiology. J Allergy (Cairo). 2011; 2011:742710. Epub 2012/01/06. doi: 10.1155/2011/742710 PMID: 22220184; PubMed Central PMCID: PMC3246780.

40. Sutcliffe A, Kaur D, Page S, Woodman L, Armour CL, Baraket M, et al. Mast cell migration to Th2 stimulated airway smooth muscle from asthmatics. Thorax. 2006; 61(8):657–62. Epub 2006/04/08. doi: 10.1136/thx.2005.056770 PMID: 16601900; PubMed Central PMCID: PMC2104682.

41. Alrashdan YA, Alkhouri H, Chen E, Lalor DJ, Poniris M, Henness S, et al. Asthmatic airway smooth muscle CXCL10 production: mitogen-activated protein kinase JNK involvement. American journal of physiology Lung cellular and molecular physiology. 2011; 302(10):L1118–27. Epub 2012/03/06. doi: 10.1152/ajplung.00322.2011 PMID: 22387292; PubMed Central PMCID: PMC3362261.

42. Ammit AJ, Lazaar AL, Irani C, O’Neill GM, Gordon ND, Amrani Y, et al. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. American journal of respiratory cell and molecular biology. 2002; 26(4):465–74. Epub 2002/03/29. doi: 10.1165/ajrccm.26.4.468 PMID: 11919083.

43. Hu R, Pan W, Fedulov AV, Jester W, Jones MR, Weiss ST, et al. MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2014; 28(5):2347–57. Epub 2014/02/14. doi: 10.1096/fj.13-247247 PMID: 24522205; PubMed Central PMCID: PMC3986841.

44. Perry MM, Baker JE, Gibeon DS, Adcock IM, Chung KF. Airway smooth muscle hyperproliferation is regulated by microRNA-221 in severe asthma. American journal of respiratory and cell molecular biology. 2014; 50(1):7–17. Epub 2013/08/16. doi: 10.1165/ajrccm.2013-0067OC PMID: 23944957; PubMed Central PMCID: PMC3930931.

45. Kuhn AR, Schlauch K, Lao R, Halayko AJ, Gerthoffer WT, Singer CA. MicroRNA expression in human airway smooth muscle cells: role of miR-25 in regulation of airway smooth muscle phenotype. American journal of respiratory cell and molecular biology. 2010; 42(4):506–13. doi: 10.1165/ajrccm.2009-0123OC PMID: 19541842.

46. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T. The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). The Journal of biological chemistry. 2011; 286(3):1786–94. doi: 10.1074/jbc.M110.169367 PMID: 21097505.

47. Tsitsiou E, Williams AE, Moschos SA, Patel K, Rossios C, Jiang X, et al. Transcriptome analysis shows activation of circulating CD8(+) T cells in patients with severe asthma. The Journal of allergy and clinical immunology. 2012; 129(1):95–103. doi: 10.1016/j.jaci.2011.08.011 PMID: 21917308.

48. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281–97. PMID: 14744438.

49. Ha TY. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw. 2011; 11(3):135–54. Epub 2011/08/24. doi: 10.4110/in.2011.11.3.135 PMID: 21860607; PubMed Central PMCID: PMC3153666.

50. Ha TY. The Role of MicroRNAs in Regulatory T Cells and in the Immune Response. Immune Netw. 2011; 11(1):11–41. Epub 2011/04/16. doi: 10.4110/in.2011.11.1.11 PMID: 21494372; PubMed Central PMCID: PMC3072673.

51. Dileepan M, Jude JA, Rao SP, Walseth TF, Panettieri RA, Subramanian S, et al. MicroRNA-708 regulates CD38 expression through signaling pathways JNK MAP kinase and PTEN/AKT in human airway smooth muscle cells. Respiratory research. 2014; 15:107. Epub 2014/09/02. doi: 10.1186/s12931-014-0107-0 PMID: 25175907; PubMed Central PMCID: PMC4156970.

52. Jude JA, Dileepan M, Subramanian S, Solwaj J, Panettieri RA Jr, Walseth TF, et al. miR-140-3p regulation of TNF-alpha-induced CD38 expression in human airway smooth muscle cells. American journal of physiology Lung cellular and molecular physiology. 2012; 303(5):L460–8. Epub 2012/07/10. doi: 10.1152/ajplung.00441.2012 PMID: 22773691; PubMed Central PMCID: PMC3468424.

53. Clarke DL, Clifford RL, Jindarat S, Proud D, Pang L, Belvisi M, et al. TNFalpha and IFNgamma synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-kappaB, and the transcriptional coactivator CREB-binding protein. The Journal of biological chemistry. 2010; 285(38):29101–10. Epub 2010/09/14. doi: 10.1074/jbc.M109.099995 PMID: 20833730; PubMed Central PMCID: PMC2937941.

54. Burgess JK, Lee JH, Ge Q, Ramsay EE, Poniris MH, Parmentier J, et al. Dual ERK and phosphatidylinositol 3-kinase pathways control airway smooth muscle proliferation: differences in asthma. Journal of cellular physiology. 2008; 216(3):673–9. doi: 10.1002/jcp.21450 PMID: 18338817.
55. Dragon S, Rahman MS, Yang J, Unruh H, Halayko AJ, Gounni AS. IL-17 enhances IL-1beta-mediated CXCL-8 release from human airway smooth muscle cells. American journal of physiology Lung cellular and molecular physiology. 2007; 292(4):L1023–9. Epub 2006/12/26. doi: 10.1152/ajplung.00306.2006 PMID: 17189320.

56. John M, Au BT, Jose PJ, Lim S, Saunders M, Barnes PJ, et al. Expression and release of interleukin-8 by human airway smooth muscle cells: inhibition by Th-2 cytokines and corticosteroids. American journal of respiratory cell and molecular biology. 1998; 18(1):84–90. Epub 1998/02/03. doi: 10.1165/ajrcmb.18.1.2813 PMID: 9448049.

57. Lin TY, Venkatesan N, Nishioka M, Kyoh S, Al-Alwan L, Baglole CJ, et al. Monocyte-derived fibrocytes induce an inflammatory phenotype in airway smooth muscle cells. Clin Exp Allergy. 2014; 44(11):1347–60. Epub 2014/09/27. doi: 10.1111/cea.12421 PMID: 25255717.

58. Rahman MS, Yamasaki A, Yang J, Shan L, Halayko AJ, Gounni AS. IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, and p38) pathways. Journal of immunology. 2006; 177(6):4064–71. Epub 2006/09/05. PMID: 16951370.

59. Tan X, Khalil N, Tesarik C, Vanapalli K, Yaputra V, Alkhouri H, et al. Th1 cytokine-induced syndecan-4 shedding by airway smooth muscle cells is dependent on mitogen-activated protein kinases. American journal of physiology Lung cellular and molecular physiology. 2012; 302(7):L700–10. Epub 2012/01/24. doi: 10.1152/ajplung.00167.2011 PMID: 22268118.

60. Chiba S, Sumi Y, Okayasu K, Okamoto T, Tateishi T, Furusawa H, et al. The c-Jun N-terminal kinase signaling pathway regulates airway smooth muscle cell proliferation. European Respiratory Journal. 2014; 44(Suppl 58).

61. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R, et al. Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. American journal of respiratory and critical care medicine. 2007; 176(1):27–35. Epub 2007/04/21. doi: 10.1164/rccm.200608-123OC PMID: 17446336.

62. Holgate ST, Yang Y, Haitchi HM, Powell RM, Holloway JW, Yoshisue H, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc. 2006; 3(5):440–3. PMID: 16790899.

63. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002; 418(6896):426–30. Epub 2002/07/12. doi: 10.1038/nature00878 PMID: 12110844.

64. Mariani F, Roncucci L. Chemerin/chemR23 axis in inflammation onset and resolution. Inflamm Res. 2015; 64(2):85–95. Epub 2014/12/31. doi: 10.1007/s00011-014-0792-7 PMID: 25548799.

65. Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 2011; 22(5):347–53. Epub 2011/11/04. PMID: 22119008.

66. Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. Journal of immunology. 2010; 185(6):3728–38. Epub 2010/08/20. doi: 10.4049/jimmunol.0902154 PMID: 20720202.

67. Girodet PO, Ozier A, Triant N, Begueret H, Oussova O, Vermejoux JM, et al. Mast cell adhesion to bronchial smooth muscle in asthma specifically depends on CD51 and CD44 variant 6. Allergy. 2010; 65(8):1004–12. Epub 2010/02/04. doi: 10.1111/j.1398-9995.2009.02308.x PMID: 20121756.

68. Lee IT, Yang CM. Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm. 2013; 2013:791231. Epub 2013/05/22. doi: 10.1155/2013/791231 PMID: 23680670; PubMed Central PMCID: PMC3649692.

69. Redhu NS, Saleh A, Halayko AJ, Ali AS, Gounni AS. Essential role of NF-kappaB and AP-1 transcription factors in TNF-alpha-induced TSLP expression in human airway smooth muscle cells. American journal of physiology Lung cellular and molecular physiology. 2011; 300(3):L479–89. Epub 2010/12/15. doi: 10.1152/ajplung.00301.2009 PMID: 21148792.

70. Eynott PR, Nath P, Leung SY, Adcock IM, Bennett BL, Chung KF. Allergen-induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N-terminal kinase. British journal of pharmacology. 2003; 140(8):1373–80. Epub 2003/11/19. doi: 10.1038/sj.bjp.0705569 PMID: 14623764; PubMed Central PMCID: PMC1574155.

71. Wuys WA, Vanaudenarde BM, Dupont LJ, Demedts MG, Verleden GM. Involvement of p38 MAPK, JNK, p42/p44 ERK and NF-kappaB in IL-1beta-induced chemokine release in human airway smooth muscle cells. Respir Med. 2003; 97(7):811–7. Epub 2003/07/12. PMID: 12854631.

72. Amiri KI, Richmond A. Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol. 2003; 74:1–36. Epub 2003/09/27. PMID: 14510072; PubMed Central PMCID: PMC3140403.
73. Genin P, Algarte M, Roof P, Lin R, Hiscott J. Regulation of RANTES chemokine gene expression requires cooperativity between NF-kappa B and IFN-regulatory factor transcription factors. Journal of immunology. 2000; 164(10):5352–61. Epub 2000/05/09. PMID: 10799898.

74. Roger T, Out T, Mukaida N, Matsushima K, Jansen H, Lutter R. Enhanced AP-1 and NF-kappaB activities and stability of interleukin 8 (IL-8) transcripts are implicated in IL-8 mRNA superinduction in lung epithelial H292 cells. The Biochemical journal. 1998; 330 (Pt 1):429–35. Epub 1998/04/16. PMID: 9461540; PubMed Central PMCID: PMC1219157.

75. Amrani Y, Ammit AJ, Panettieri RAJ. Tumor necrosis factor receptor (TNFR) 1, but not TNFR2, mediates tumor necrosis factor-alpha-induced interleukin-6 and RANTES in human airway smooth muscle cells: role of p38 and p42/44 mitogen-activated protein kinases. Mol Pharmacol. 2001; 60(4):646–55. PMID: 11562425

76. Berkman N, Krishnan VL, Gilbey T, Newton R, O'Connor B, Barnes PJ, et al. Expression of RANTES mRNA and protein in airways of patients with mild asthma. American journal of respiratory and critical care medicine. 1996; 154(6 Pt 1):1804–11. PMID:8970374

77. Deshpande DA, White TA, Guedes AG, Walseth TF, Lund FE, et al. Altered airway responsiveness in CD38-deficient mice. American journal of respiratory cell and molecular biology. 2005; 32 (2):149–56. Epub 2004/11/24. doi: 10.1165/rcmb.2004-0243OC PMID: 15557017.

78. Guedes AG, Deshpande DA, Dileepan M, Walseth TF, Panettieri RA Jr, Subramanian S, et al. CD38 and airway hyper-responsiveness: studies on human airway smooth muscle cells and mouse models. Canadian journal of physiology and pharmacology. 2015; 93(2):145–53. Epub 2015/01/17. doi: 10.1139/cjpp-2014-0410 PMID: 25594684.

79. Guedes AG, Paulin J, Rivero-Nava L, Kita H, Lund FE, Kannan MS. CD38-deficient mice have reduced airway hyperresponsiveness following IL-13 challenge. American journal of Lung Cellular and Molecular Physiology. 2015; 93(2):145–53. Epub 2015/01/17. doi: 10.1139/cjpp-2014-0410 PMID: 25594684.

80. Garantziotis S, Li Z, Potts EN, Kimata K, Zhuo L, Morgan DL, et al. Hyaluronan mediates ozone-induced airway hyperresponsiveness in mice. The Journal of biological chemistry. 2009; 284 (17):11309–17. Epub 2009/01/24. doi: 10.1074/jbc.M802400200 PMID: 19164299; PubMed Central PMCID: PMC2670136.

81. Katoh S, Matsumoto N, Kawakita K, Tominaga A, Kincade PW, Matsukura S. A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest. 2003; 111(10):1563–70. Epub 2003/05/17. doi: 10.1172/JCI16583 PMID: 12750406.

82. Al Heialy S, Risse PA, Zeroual MA, Roman HN, Tsuchiya K, Siddiqui S, et al. T cell-induced airway smooth muscle cell proliferation via the epidermal growth factor receptor. American journal of respiratory cell and molecular biology. 2013; 49(4):563–70. Epub 2013/05/10. doi: 10.1165/rcmb.2012-0356OC PMID: 23656597.

83. Ishikawa T, Nakayama K, Mikami J, Ito S, Takasaka N, Yumino Y, et al. The involvement of thrombospondin-1 in COPD pathogenesis through IL-8 production. European Respiratory Journal. 2013; 42 (Suppl 57).

84. Androlewicz MJ. The role of tapasin in MHC class I antigen assembly. Immunol Res. 1999; 20(2):79–88. Epub 1999/12/02. PMID: 10580633.

85. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964–1999. J Allergy Clin Immunol. 2002; 109:89–94.

86. Hirst SJ, Martin JG, Bonacci JV, Chan V, Fixman ED, Hamid QA, et al. Proliferative aspects of airway smooth muscle. The Journal of allergy and clinical immunology. 2004; 114(2 Suppl):S2–17. Epub 2004/08/17. doi: 10.1016/j.jaci.2004.04.039 PMID: 15309015.

87. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012; 42:859–8. doi: 10.1111/j.1365-2223.2011.03929.x PMID: 22251060